GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients

Clinical Trial Data to be Presented at The Liver Meeting(®) 2012 in Boston BOSTON, Nov. 11, 2012 - GlobeImmune, Inc., today announced Phase 2b clinical data showing that GI-5005, a Tarmogen(®) product candidate for the treatment of chronic hepatitis C virus (HCV) infection, improved virologic clearance of HCV in combination with pegylated-interferon plus ribavirin (P/R) in genotype 1, IL28B T/T patients...

New York, 11/11/2012 (informazione.news - comunicati stampa - varie)
Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE